Advanced searches left 3/3

Catheter Ablation - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial

This research shows a significant benefit of CA over medical therapy in terms of VT-free survival, surviving without the VT storm, and VT burden. CA has been shown to be safe in eliminating VT in NICM patients who have failed AADs, resulting in a decrease in VT burden and AAD use over a long-term follow-up, according to observational studies. Further, there are few studies on the effectiveness of CA in early ICM with VT, or advanced ICM with VT, and this is not representative of the true-world situation of patients with structural heart disease presenting with VT.

Source link: https://clinicaltrials.gov/ct2/show/NCT05524077


AUGMENTED WIDE AREA CIRCUMFERENTIAL CATHETER ABLATION FOR REDUCTION OF ATRIAL FIBRILLATION RECURRENCE - A RANDOMIZED CLINICAL TRIAL (The AWARE Trial)

One of the most common challenges faced by physicians is the problem of PV reconnection and recurrent AF following catheter ablation for paroxysmal AF. Rationale: The understanding of the role of contact force in catheter ablation is a major step forward in the field of catheter ablation for AF. A few small clinical studies have shown the effectiveness and reliability of contact force guided catheter ablation in lowering PV reconnection and AF recurrence. The investigators have devised a new augmented ablation scheme and will try it against the new gold standard ablation method. Our aim is to explore an "augmented-wide circumferential catheter ablation strategy" that may help reduce the incidence of pulmonary vein reconnection and AF recurrence in patients with paroxysmal AF. Hypothesis: In patients with symptomatic paroxysmal AF, an enhanced-wide area circumferential catheter ablation program would result in less electrocardiographically mapped atrial arrhythmias recurrences in comparison to conventional wide-area catheter ablation. All four pulmonary veins in the trial's control arm will be subjected to wide area circumferential catheter ablation around the endpoint of electrical isolation. After completion of the lesion set, Dormant PV conduction will be tested using adenosine, and additional leions will be delivered to eliminate dormant PV conduction.

Source link: https://clinicaltrials.gov/ct2/show/NCT02150902


The Impact of Atrial Pressure Change Before and After One-stop Procedure Combining Catheter Ablation and Left Atrial Appendage Closure on the Prognosis of Patients With Atrial Fibrillation

This study was designed to assess the left and right atrial pressure changes before and after catheter ablation and left atrial appendage closure, as well as the effects of the pressure change on clinical outcomes. i. Atrial fibrillation detected by 12-lead ECG or Holter that lasted for longer than 30 seconds within the preceding six months; i. e. At risk of stroke and/or bleeding if left atrial appendage closure, those who meet at least one of the following are at risk of stroke and/or bleeding; Contraindicated to oral anticoagulation; Refused OAC therapy, but thoroughly aware of the danger and benefits of OAC therapy. Only for pulmonary vein isolation should ablation be done. Before transseptal puncture and after combined procedure is achieved, proper atrial pressure should be determined for atrial pressure measurement. After transseptal puncture, after pulmonary vein isolation, and after LAAC, left atrial pressure should be measured at three timepoints: after transseptal puncture, after transseptal puncture, and after LAAC. Through a Swartz transseptal puncture sheath, Atrial pressure is measured. stoke/transient ischemic disease and death due to cardiovascular disease, according to a primary composite endpoint of rehospitalization due to heart failure and death due to cardiovascular disease, as well as secondary endpoints including: 1. all-cause mortality 2. evaluation of left atrial appendage closures. The anti-thromboembolic regimen should include 3-month OAC therapy and three-month double anti-platelet therapy, as well as lifelong single anti-platelet therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT05106270


High-density Activation Mapping of the Slow Pathway During Sinus Rhythm: a New and Simple Method to Guide Catheter Ablation in Patients With Typical Atrioventricular Nodal Reentrant Tachycardia

During an electrophysiological investigation, Atrioventricular nodal reentrant tachycardia is the most common supraventricular tachycardia inducible. With a high-density mapping catheter, you can determine a fast and safe catheter ablation scheme. The aim of this research is to determine the presence and patterns of specific electrograms indicating low pathway potentials and even analysis Koch's triangle pattern activation during sinus rhythm and/or atrial extraestimulus. SP signals may have disappeared after the RF procedure when doing a new 3D HDM, for example. A control group of patients with AVN dual physiology should demonstrate the absence of fragmented/slow conduction zones.

Source link: https://clinicaltrials.gov/ct2/show/NCT05531903


RAD 1901: Noninvasive Cardiac Radioablation for Ventricular Tachycardia Refractory to Medication and Catheter Ablation

Ventricular tachycardia is a common, fast heart rhythm resulting from intermittent electrical conduction in the ventricles of the heart. The majority of VT cases are caused by Coronary heart disease. Both monitor the heart rhythm continuously and administer medication in response to tachycardia that meets pre-programmed detection criteria. Electrophysiologic mapping can be used to localize the arrhythmogenic focus, which can be then ablated with cardiac catheter radiofrequency ablation, for patients with VT refractory to medical therapy requiring multiple ICD shocks. Stereotactic body radiotherapy is a treatment used most commonly as a cancer cure, in which a targeted, high dose of radiation is delivered to a target. Noninvasive targeting of the arrhythmogenic substrate with SBRT is an emerging method with demonstrated promising results for patients with VT refractory to medication and catheter ablation.

Source link: https://clinicaltrials.gov/ct2/show/NCT04757688


Evaluating Active Esophageal Cooling During Cardiac Ablation Procedures

This is a prospective, pilot study using the Attune Medical esophageal heat transfer device to rapidly cool the esophagus during RF ablation procedures. According to the Instructions for Use, the esophageal heat transfer unit will be introduced into the esophagus after the patient is intubated. Posterior left atrial wall ablation using standard protocols will only be performed after the esophageal heat transfer device has reached a temperature of 4-6 degrees C for at least two minutes.

Source link: https://clinicaltrials.gov/ct2/show/NCT04063761


Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

De Novo PAF is a group of subjects undergoing first ablation procedure for PAF with no previous left atrial ablation. IN THE STUDY: SYSTEM USED IN THE STUDY — IntellaNav Open-Irrigated Catheter IntellaNav Brought Ablation Catheter IntellaNav Open-Irrigated Catheter The report will include the following Boston Scientific Open-Irrigated Catheters in geographies where commercially approved for PAF ablation: IntellaNav Open-Irrigated Catheter IntellaNav MiFi Open-Irrigated —Re: The study will include the following: The research will be used in the study SYSTEM USED / /In the /Irrigated Catheter IntellaNav Matrigeneter IntellaNav Catheter Intella eta Catheter IntellaNav Macro Athenter IntellaNav Mamo Embeta Catheter IntellaTirrigated Catheter IntellaTirrigated Ablation Catheter IntellaNav Maheter IntellaNav MiFi Ablation Catheter IntellaNav Ablation Catheter IntellaMo Ablation All subjects complying with the enrollment criteria, signing the agreement, and performing the index procedure with the study equipment will be monitored for three years until the FDA's completion of the PAS design guidelines are followed for three years.

Source link: https://clinicaltrials.gov/ct2/show/NCT03729830

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions